Feasibility of fludarabine added to VAD during induction therapy in multiple myeloma: A randomised phase II-study

European Journal of Haematology

Volumn 70, Issue 6, 2003, Pages 379-383

  Björkstrand, Bo ^a   Rasmussen, Thomas ^b   Remes, Kari ^c   Gruber, Astrid ^a   Pelliniemi, Tarja Terttu ^c   Johnsen, Hans E ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^c TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

B cells; Clonal cells; Fludarabine; Multiple myeloma; Treatment

Indexed keywords

DEXAMETHASONE; DOXORUBICIN; FLUDARABINE; VINCRISTINE;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOPHENOTYPING; INFECTION; MALE; MULTIPLE MYELOMA; NEUTROPENIA; PATIENT MONITORING; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN INFECTION; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; B-LYMPHOCYTES; CLONE CELLS; CYTARABINE; DEXAMETHASONE; FEASIBILITY STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM CIRCULATING CELLS; REMISSION INDUCTION; VIDARABINE; VINCRISTINE;

EID: 0038472468     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0609.2003.00068.x     Document Type: Article

References (20)

1. ATTAL M, HAROUSSEAU JL, STOPPA AM, et al. A prospective randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996;335:91-97.
2. BARLOGIE B, JAGANNATH S, DESIKAN KR, et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999;93:55-65.
3. LENHOFF S, HJORTH M, HOLMBERG E, et al. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Blood 2000;95:7-11.
4. GAHRTON G, SVENSSON H, CAVO M, et al. Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-1993 and 1994-1998 at EBMT centers. Br J Haematol 2001;113:209-216.
5. BJÖRKSTRAND B, LJUNGMAN P, SVENSSON H, et al. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma - a retrospective case-matched study from the European Group for Blood and Marrow Transplantation. Blood 1996;88:4711-4718.
6. BILLADEAU D, QUAM L, THOMAS W, KAY N, GREIPP P, KYLE R, OKEN MM, van NESS B. Detection and quantification of malignant cells in the peripheral blood of multiple myeloma patients. Blood 1992;80:1818-1824.
7. CORRADINI P, BOCCADORO M, VOENA C, PILERI A. Evidence for a bone marrow B cell transcribing malignant plasma cell VDJ joined to Cμ sequence in IgG and IgA secreting multiple myelomas. J Exp Med 1993;178:1091-1096.
8. PILARSKI LM, BELCH AR. Circulating monoclonal B cells expressing P glycoprotein may be a reservoir of multidrug-resistant disease in multiple myeloma. Blood 1994;83:724-736.
9. BERGSAGEL PL, MASELLIS SMITH A, SZCZEPEK A, MANT MJ, BELCH AR, PILARSKI LM. In multiple myeloma, clonotypic B lymphocytes are detectable among CD19+ peripheral blood cells expressing CD38, CD56, and monotypic Ig light chain. Blood 1995;85:436-447.
10. SZCZEPEK AJ, SEEBERGER K, WIZNIAK J, MANT MJ, BELCH AR, PILARSKI LM. A high frequency of circulating B cells share clonotypic Ig heavy-chain VDJ rearrangements with autologous bone marrow plasma cells in multiple myeloma, as measured by single-cell and in situ reverse transcriptase-polymerase chain reaction. Blood 1998;92:2844-2855.
11. ROTTENBURGER C, KIEL K, BÖSING T, CREMER FW. Clonotypic CD20+ and CD19+ B-cells in peripheral blood of patients with multiple myeloma post high-dose therapy and peripheral blood stem cell transplantation. Br J Haematol 1999;106:545-552.
12. KIEL K, CREMER FW, ROTTENBURGER C, KALLMEYER C, EHRBRECHT E, ATZBERGER A, HEGENBART U, GOLDSCHMIDT H, MOOS M. Analysis of circulating tumor cells in patients with multiple myeloma during the course of high-dose therapy with peripheral blood stem cell transplantation. Bone Marrow Transplant 1999;23:1019-1027.
13. KRAUT EH, CROWLEY JJ, GREVER MR, KEPPEN MD, BONNET JD, HYNES HE, SALMON SE. Phase II study of fludarabine phosphate in multiple myeloma. A Southwest Oncology Group study. Invest New Drugs 1990;8:199-200.
14. GALMARINI CM, MACKEY JR, DUMONTET C. Nucleoside analogues: mechanisms of drug resistance and reversal strategies. Leukemia 2001;15:875-890.
15. BARLOGIE B, SMITH L, ALEXANIAN R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 1984;310:1353-1356.
16. RASMUSSEN T, JENSEN L, HONORE L, ANDERSEN H, JOHNSEN HE. Circulating clonal cells in multiple myeloma do not express CD34 mRNA, as measured by single-cell and realtime RT-PCR assays. Br J Haematol 1999;107:818-824.
17. RASMUSSEN T, JENSEN L, HONORÉ L, JOHNSEN HE. Frequency and kinetics of polyclonal and clonal B-cells in the peripheral blood of patients being treated for multiple myeloma. Blood 2000;96:4357-4359.
18. RASMUSSEN T, BJÖRKSTRAND B, ANDERSEN H, GAARDSDAL E, JOHNSEN HE. Efficacy and safety of CD34-selected and CD19-depleted autografting in multiple myeloma patients: a pilot study. Exp Hematol 2002;30:82-88.
19. BILLADEAU D, AHMANN G, GREIPP P, van NESS B. The bone marrow of multiple myeloma patients contains B cell populations at different stages of differentiation that are clonally related to the malignant plasma cell. J Exp Med 1993;178:1023-1031.
20. RASMUSSEN T. The presence of circulating clonal CD19+ cells in multiple myeloma. Leuk Lymphoma 2001;42:1359-1366.